BGLC BioNexus Gene Lab Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: BGLC

Price (delayed)

$0.6

Market cap

$10.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.18

Enterprise value

$8.12M

Highlights
BioNexus Gene Lab's equity has increased by 45% YoY
The gross margin is up by 18% year-on-year
The quick ratio has dropped by 50% since the previous quarter but it is up by 24% year-on-year
BioNexus Gene Lab's gross profit has increased by 6% YoY but it has decreased by 5% QoQ
The debt has surged by 158% year-on-year and by 6% since the previous quarter
The revenue has declined by 11% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.bionexusgenelab.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of BGLC
Market
Shares outstanding
17.67M
Market cap
$10.6M
Enterprise value
$8.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.1
Price to sales (P/S)
0.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.83
Earnings
Revenue
$9.77M
EBIT
-$2.59M
EBITDA
-$2.49M
Free cash flow
-$1.45M
Per share
EPS
-$0.18
Free cash flow per share
-$0.09
Book value per share
$0.55
Revenue per share
$0.62
TBVPS
$0.72
Balance sheet
Total assets
$11.4M
Total liabilities
$1.74M
Debt
$146,594
Equity
$9.66M
Working capital
$6.42M
Liquidity
Debt to equity
0.02
Current ratio
4.93
Quick ratio
2.17
Net debt/EBITDA
1
Margins
EBITDA margin
-25.4%
Gross margin
13.6%
Net margin
-26.9%
Operating margin
-31.5%
Efficiency
Return on assets
-27%
Return on equity
-33%
Return on invested capital
-42.2%
Return on capital employed
-26.5%
Return on sales
-26.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BGLC stock price

How has the BioNexus Gene Lab stock price performed over time
Intraday
0%
1 week
1.69%
1 month
1.18%
1 year
83.09%
YTD
13.21%
QTD
-15.01%

Financial performance

How have BioNexus Gene Lab's revenue and profit performed over time
Revenue
$9.77M
Gross profit
$1.33M
Operating income
-$3.08M
Net income
-$2.63M
Gross margin
13.6%
Net margin
-26.9%
The gross margin is up by 18% year-on-year
The net income has grown by 15% from the previous quarter
The operating income has increased by 12% since the previous quarter
The revenue has declined by 11% year-on-year and by 5% since the previous quarter

Growth

What is BioNexus Gene Lab's growth rate over time

Valuation

What is BioNexus Gene Lab stock price valuation
P/E
N/A
P/B
1.1
P/S
0.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.83
BioNexus Gene Lab's equity has increased by 45% YoY
The revenue has declined by 11% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is BioNexus Gene Lab business performance
The return on equity rose by 23% since the previous quarter
The ROA rose by 21% QoQ
The return on invested capital has increased by 17% since the previous quarter
The ROS has grown by 8% from the previous quarter

Dividends

What is BGLC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BGLC.

Financial health

How did BioNexus Gene Lab financials performed over time
BioNexus Gene Lab's current ratio has soared by 64% YoY
The quick ratio has dropped by 50% since the previous quarter but it is up by 24% year-on-year
The debt is 98% smaller than the equity
The debt has surged by 158% year-on-year and by 6% since the previous quarter
The company's debt to equity has surged by 100% QoQ and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.